Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer Advancing Once-Daily Danuglipron For Obesity

Jul 11 2024

• By Jessica Merrill

Pfizer — Pfizer updated investors on the development of danuglipron • Source: Shutterstock

Related Content

Pfizer’s Mixed Readout Places Doubt On Oral GLP-1 For Obesity

Dec 01 2023

Pfizer Sees Once Daily Danuglipron In The “Reasonable Future”

Aug 02 2023

With Competition Closing In, Novo Details Oral Semaglutide Weight Loss At ADA

Jun 26 2023

Related Companies

Pfizer Inc.

Novo Nordisk A/S

Eli Lilly and Company

Additional Topics

Research & Development Clinical Trials Business Strategies Metabolic Disorders BioPharmaceutical

More from Alimentary/Metabolic

More from Therapeutic Category

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.